Stock NUVB NUVATION BIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Nuvation Bio Inc.

Equities

NUVB

US67080N1019

Market Closed - Nyse
Other stock markets
 21:00:03 28/06/2024 BST 		5-day change 1st Jan Change
2.92 USD -3.95% Intraday chart for Nuvation Bio Inc. -4.26% +93.38%
06-24 Nuvation Bio Inc.(NYSE:NUVB) added to S&P Pharmaceuticals Select Industry Index CI
06-13 Nuvation Bio Insider Bought Shares Worth $500,089, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Nuvation Bio Insider Bought Shares Worth $500,089, According to a Recent SEC Filing
Nuvation Bio Inc. Announces Data from Pivotal Phase 2 Trust-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, Publishes in Journal of Clinical Oncology and Reports at 2024 ASCO Annual Meeting
Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours
Nuvation Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Nuvation Bio Closes Acquisition of AnHeart Therapeutics
Nuvation Bio Inc. Announces Appointment of Directors
Nuvation Bio Inc. completed the acquisition of AnHeart Therapeutics Ltd
Nuvation Bio Inc. Appoints Colleen Sjogren as Chief Commercial Officer
Nuvation Bio Shares Jump After Jefferies Upgrade
Top Premarket Gainers
Nuvation Bio Agrees to Acquire AnHeart Therapeutics in All-Stock Deal -- Shares Fall
Nuvation Bio Doses First Patient in Phase 1/2 Study of Advanced Solid Tumor Treatment
Nuvation Bio Inc. Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
Nuvation Bio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Nuvation Bio Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Nuvation Bio Receives US FDA Clearance for Investigational New Drug Application for NUV-1511
Nuvation Bio Inc. Announces Appointment of Robert Mashal to Its Board of Directors
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
Nuvation Bio Inc. Announces Resignation of Oleg Nodelman from Board of Directors
Nuvation Bio Inc. Appoints Moses Makunje as Principal Accounting Officer and Principal Financial Officer
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NUVB Stock
  4. News Nuvation Bio Inc.
  5. Other languages